Insulet (PODD) to Release Quarterly Earnings on Thursday

Insulet (NASDAQ:PODD - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Insulet to post earnings of $0.81 per share and revenue of $543.20 million for the quarter. Insulet has set its Q1 2025 guidance at EPS and its FY 2025 guidance at EPS.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. On average, analysts expect Insulet to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Insulet Stock Up 2.7 %

Shares of Insulet stock traded up $6.76 during trading hours on Friday, reaching $257.01. 838,676 shares of the company's stock were exchanged, compared to its average volume of 717,346. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The stock has a market cap of $18.05 billion, a P/E ratio of 44.39, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a 50 day moving average of $257.51 and a two-hundred day moving average of $262.48.

Insider Transactions at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on PODD shares. Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. Piper Sandler boosted their target price on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Barclays increased their price target on Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday. Raymond James reaffirmed an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Canaccord Genuity Group increased their price target on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and a consensus target price of $293.94.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.